

MD Anderson Cancer Center Clinical Trials for Gynecological Cancers

To refer online: <https://my.mdanderson.org>

To refer by phone, call the Gynecologic Oncology Center: 713-792-6810

To discuss clinical trials, call Ljiljana Milojevic, coordinator, Clinical Research Program: 713-792-8578

Below is a non-exhaustive list of clinical trials open in the Department of Gynecologic Oncology and Reproductive Medicine. It is current as of February 12, 2015, and is subject to change. Please call to confirm availability of clinical trials.

Ovarian – Fallopian Tube – Peritoneum Cancers

Primary Epithelial

2011-0800 (P.I. Lois Ramondetta, M.D.): Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

2014-0474 (P.I. Shannon Westin, M.D.): POSITION: A Pilot Study of InducTion PARP InhibitiON in ovarian cancer

Recurrent Platinum Sensitive

GOG 0213 (P.I. Robert Coleman, M.D.): Phase III Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agent: Bevacizumab

Secondary Maintenance

2013-0208 (P.I. Robert Coleman, M.D.): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Rucaparib as Switch Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, Relapsed High-Grade Serous Ovarian Cancer

Recurrent Platinum Resistant

2013-0190 (P.I. Robert Coleman, M.D.): Phase Ib/II Study of Demcizumab plus Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

Recurrent Platinum Sensitive/Platinum Resistant

2012-0759 (P.I. Jubilee Brown, M.D.): Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients with Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

2014-0160 (P.I. Shannon Westin, M.D.): A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

2013-0784 (P.I. Shannon Westin, M.D.): A phase Ib study of the oral PARP inhibitor olaparib with the oral mTORC1/2 inhibitor AZD2014 or the oral AKT inhibitor AZD5363 for recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

Ovarian-Rare Tumors

Low-Grade Serous, Persistent, Recurrent

GOG 0281 (P.I. Alpa Nick, M.D.): Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Recurrent Sex Cord Stromal Tumor

GOG 0264 (P.I. Jubilee Brown, M.D.): Phase II, Randomized Trial of Paclitaxel and Carboplatin Versus Bleomycin, Etoposide and Cisplatin for

Newly Diagnosed Advanced-Stage and
Recurrent Chemonaive Sex-Cord Stromal
Tumors

Endometrium/Uterus Cancer

Primary, Post Surgery

2013-1035 (P.I. Pamela Soliman, M.D.): A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer

Advanced/Recurrent

2012-0543 (P.I. Pamela Soliman, M.D.): Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole and Metformin in Patients with Advanced or Recurrent Endometrial Carcinoma

GOG 02290 (P.I. Shannon Westin, M.D.): Randomized Phase II Study with a Phase I Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, and AKT Inhibitor in Patients with Recurrent or Persistent Endometrial Cancer

2013-0734 (P.I. Shannon Westin, M.D.): A phase Ib study of the oral PARP inhibitor olaparib with the oral mTORC1/2 inhibitor AZD2014 or the oral AKT inhibitor AZD5363 for recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

2014-0160 (P.I. Shannon Westin, M.D.): A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Cervical Cancer Newly Diagnosed

RTOG 0724 (P.I. Ann Klopp, M.D., Ph.D.): Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy

Locally Advanced (Stages 1B2-IVA)

GOG 0274 (P.I. Lois Ramondetta, M.D.): Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial (ANZGOG 0902 /GOG 0274/ RTOG 1174)

Advanced, Previously Treated

2014-0160 (P.I. Shannon Westin, M.D.): A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Surgical Trials

2007-0800 (P.I. Pedro Ramirez, M.D.): Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients with Early-Stage Cervical Cancer

2008-0118 (P.I. Kathleen Schmeler, M.D.): Conservative Surgery for Women with Low-Risk, Early-Stage Cervical Cancer (Stage 1A2 or 1B1)

2010-0952 (P.I. Michael Frumovitz, M.D.): Phase III Randomized Study of Pretherapeutic Para-Aortic Lymphadenectomy in Women with Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy (LILACs)

For more information, including eligibility criteria,
please visit our website:

www.mdanderson.org/gynonctrials

